Cocrystal Pharma Inc Financials
This page shows Cocrystal Pharma Inc (COCP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The dominant mechanic is a research-stage cash model: operating costs consume cash while financing periodically replenishes the balance sheet.
In FY2025, operating cash flow of-$8.2M nearly matched net income of-$8.8M , indicating that reported losses closely translated into cash needs rather than being driven mainly by non-cash adjustments. Free cash flow was also-$8.2M and capital expenditures were just$12K , reinforcing a low-capital-intensity model whose funding burden comes from ongoing research and administration.
The loss narrowed from
The reported cash-and-investment balance represented 10.3 months of the latest annual operating outflow, while the current ratio was 3.7x; that provides a concrete view of short-term liquidity without implying a forecast. Debt-to-equity reached 0.5x in FY2025, while financing cash flow was
Financial Health Signals
Cocrystal Pharma Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Cocrystal Pharma Inc passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Cocrystal Pharma Inc reported a net loss of $8.8M while operations used $8.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Cocrystal Pharma Inc reported an operating loss of $9.0M against $134K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Cocrystal Pharma Inc's EBITDA was -$8.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 49.6% from the prior year.
Cocrystal Pharma Inc reported -$8.8M in net income in fiscal year 2025. This represents an increase of 49.5% from the prior year.
Cocrystal Pharma Inc earned -$0.78 per diluted share (EPS) in fiscal year 2025. This represents an increase of 54.7% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Cocrystal Pharma Inc recorded an outflow of $8.2M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 50.3% from the prior year.
Cocrystal Pharma Inc held $7.0M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Cocrystal Pharma Inc's ROE was -139.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 44.3 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Cocrystal Pharma Inc invested $5.1M in research and development in fiscal year 2025. This represents a decrease of 59.7% from the prior year.
Cocrystal Pharma Inc invested $12K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 50.0% from the prior year.
Not reported for fiscal year 2025.
COCP Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $105K-53.3% | $225K | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $2.1M+56.2% | $1.4M | N/A | $954K-15.0% | $1.1M-17.5% | $1.4M | N/A | $3.2M |
| SG&A Expenses | $1.1M-5.2% | $1.2M | N/A | $1.1M+15.1% | $986K+0.5% | $981K | N/A | $1.8M |
| Operating Income | -$3.2M-35.1% | -$2.4M | N/A | -$2.1M+0.9% | -$2.1M+10.0% | -$2.3M | N/A | -$5.0M |
| Interest Expense | -$10K+54.5% | -$22K | N/A | -$22K+21.4% | -$28K+24.3% | -$37K | N/A | -$111K |
| Income Tax | N/A | $0 | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$3.2M-37.6% | -$2.3M | N/A | -$2.0M+0.3% | -$2.1M+10.7% | -$2.3M | N/A | -$4.9M |
| EPS (Diluted) | -$0.23-35.3% | -$0.170.0% | -$0.17+10.5% | -$0.19+5.0% | -$0.20+13.0% | -$0.23+28.1% | -$0.32+34.7% | -$0.49 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
COCP Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $4.6M-37.4% | $7.4M-23.5% | $9.7M-7.0% | $10.4M+22.8% | $8.5M-20.2% | $10.7M-20.8% | $13.5M-17.1% | $16.2M |
| Current Assets | $3.2M-45.5% | $5.9M-27.0% | $8.1M-7.4% | $8.8M+29.8% | $6.8M-23.4% | $8.8M-23.8% | $11.6M-18.8% | $14.3M |
| Cash & Equivalents | $2.2M-53.7% | $4.7M-33.3% | $7.0M-9.1% | $7.7M+62.2% | $4.8M-31.1% | $6.9M-29.8% | $9.9M-24.7% | $13.1M |
| Total Liabilities | $3.6M+8.9% | $3.3M-2.1% | $3.4M+21.8% | $2.8M-12.5% | $3.2M-5.5% | $3.4M-14.7% | $3.9M+11.4% | $3.5M |
| Current Liabilities | $2.6M+17.4% | $2.2M+0.9% | $2.2M+45.4% | $1.5M-17.0% | $1.8M-5.2% | $1.9M-20.5% | $2.4M+24.6% | $1.9M |
| Total Equity | $1.0M-74.6% | $4.1M-35.0% | $6.3M-17.4% | $7.7M+43.8% | $5.3M-27.0% | $7.3M-23.3% | $9.5M-25.0% | $12.7M |
| Retained Earnings | -$347.7M-0.9% | -$344.5M-0.7% | -$342.2M-0.7% | -$339.8M-0.6% | -$337.8M-0.6% | -$335.7M-0.7% | -$333.4M-1.0% | -$330.2M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
COCP Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.5M-7.5% | -$2.3M-34.8% | -$1.7M-27.5% | -$1.4M+36.8% | -$2.2M+26.7% | -$2.9M+7.0% | -$3.2M+38.3% | -$5.1M |
| Capital Expenditures | N/A | N/A | $0 | N/A | N/A | N/A | $0 | $0 |
| Free Cash Flow | N/A | N/A | -$1.7M | N/A | N/A | N/A | -$3.2M+38.3% | -$5.1M |
| Investing Cash Flow | N/A | N/A | $0 | N/A | N/A | N/A | $0 | $0 |
| Financing Cash Flow | N/A | N/A | $1.0M | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
COCP Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -3032.4% | -1047.1% | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | -3013.3% | -1021.8% | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -303.1%-247.2pp | -55.9% | N/A | -26.7%+11.8pp | -38.5%-7.0pp | -31.5% | N/A | -38.9% |
| Return on Assets | -68.1%-37.1pp | -31.0% | N/A | -19.6%+4.5pp | -24.2%-2.6pp | -21.6% | N/A | -30.4% |
| Current Ratio | 1.24-1.4x | 2.66-1.0x | 3.68-2.1x | 5.78+2.1x | 3.69-0.9x | 4.57-0.2x | 4.77-2.5x | 7.32 |
| Debt-to-Equity | 3.45+2.6x | 0.80+0.3x | 0.53+0.2x | 0.36-0.2x | 0.59+0.1x | 0.460.0x | 0.41+0.1x | 0.28 |
Not reported in any period shown, so not listed: Gross Margin, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Where Cocrystal Pharma Inc Ranks
Frequently Asked Questions
Is Cocrystal Pharma Inc profitable?
No, Cocrystal Pharma Inc (COCP) reported a net income of -$8.8M in fiscal year 2025.
What is Cocrystal Pharma Inc's EBITDA?
Cocrystal Pharma Inc (COCP) had EBITDA of -$8.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Cocrystal Pharma Inc's return on equity (ROE)?
Cocrystal Pharma Inc (COCP) has a return on equity of -139.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Cocrystal Pharma Inc's free cash flow?
Cocrystal Pharma Inc (COCP) recorded an outflow of $8.2M in free cash flow during fiscal year 2025. This represents a 50.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Cocrystal Pharma Inc's operating cash flow?
Cocrystal Pharma Inc (COCP) recorded an outflow of $8.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Cocrystal Pharma Inc's total assets?
Cocrystal Pharma Inc (COCP) had $9.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Cocrystal Pharma Inc's capital expenditures?
Cocrystal Pharma Inc (COCP) invested $12K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Cocrystal Pharma Inc spend on research and development?
Cocrystal Pharma Inc (COCP) invested $5.1M in research and development during fiscal year 2025.
What is Cocrystal Pharma Inc's current ratio?
Cocrystal Pharma Inc (COCP) had a current ratio of 3.68 as of fiscal year 2025, which is generally considered healthy.
What is Cocrystal Pharma Inc's debt-to-equity ratio?
Cocrystal Pharma Inc (COCP) had a debt-to-equity ratio of 0.53 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Cocrystal Pharma Inc's return on assets (ROA)?
Cocrystal Pharma Inc (COCP) had a return on assets of -90.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Cocrystal Pharma Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Cocrystal Pharma Inc (COCP) held $7.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $8.2M over that year. Dividing the one by the other, the reported balance equals about 10 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Cocrystal Pharma Inc's Piotroski F-Score?
Cocrystal Pharma Inc (COCP) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cocrystal Pharma Inc's earnings high quality?
Cocrystal Pharma Inc (COCP) reported a net loss of $8.8M while operations used $8.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Cocrystal Pharma Inc cover its interest payments?
Cocrystal Pharma Inc (COCP) reported an operating loss of $9.0M against $134K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.